Early astrocytosis in autosomal dominant Alzheimer’s disease measured in vivo by multi-tracer positron emission tomography

[1]  D. Brooks.  Imaging neuroinflammation in Alzheimer’s and other dementias: recent advances and future directions , 2016, Neurobiology of Aging.

[2]  D. Brooks,et al.  Imaging neuroinflammation in Alzheimer's disease and other dementias: Recent advances and future directions , 2015, Alzheimer's & Dementia.

[3]  R. von Bernhardi,et al.  Microglial cell dysregulation in brain aging and neurodegeneration , 2015, Front. Aging Neurosci..

[4]  David Bartrés-Faz,et al.  Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease , 2015, Neurobiology of Aging.

[5]  Burkhard Becher,et al.  Immune attack: the role of inflammation in Alzheimer disease , 2015, Nature Reviews Neuroscience.

[6]  M. Heneka,et al.  Innate immunity in Alzheimer's disease , 2015, Nature Immunology.

[7]  R. Boellaard,et al.  Quantification of [18F]DPA-714 binding in the human brain: initial studies in healthy controls and Alzheimer's disease patients , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  K. Blennow,et al.  Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.

[9]  Stephen F. Carter,et al.  Astrocytosis measured by 11C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer’s patients , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  K. Blennow,et al.  Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease , 2014, Dementia and Geriatric Cognitive Disorders Extra.

[11]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[12]  S. Pimplikar.  Neuroinflammation in Alzheimer’s Disease: from Pathogenesis to a Therapeutic Target , 2014, Journal of Clinical Immunology.

[13]  M. Sofroniew,et al.  Reactive Gliosis and the Multicellular Response to CNS Damage and Disease , 2014, Neuron.

[14]  Nick C Fox,et al.  Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease , 2013, Proceedings of the National Academy of Sciences.

[15]  V. Vishnu.  Implications of presymptomatic change in thalamus and caudate in Alzheimer's disease. , 2013, Brain : a journal of neurology.

[16]  A. Nordberg,et al.  3H-Deprenyl and 3H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brain , 2013, Journal of Neuroinflammation.

[17]  Nick C Fox,et al.  Reply: Implications of presymptomatic change in thalamus and caudate in Alzheimer’s disease , 2013, Brain : a journal of neurology.

[18]  Francis J McMahon,et al.  In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. , 2013, Brain : a journal of neurology.

[19]  J. Growdon,et al.  Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. , 2013, Journal of neuropathology and experimental neurology.

[20]  B. Gulyás,et al.  In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimer’s disease patients , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  Alan A. Wilson,et al.  Distribution of Monoamine Oxidase Proteins in Human Brain: Implications for Brain Imaging Studies , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  Gaël Chételat,et al.  Alzheimer disease: Aβ-independent processes—rethinking preclinical AD , 2013, Nature Reviews Neurology.

[23]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[24]  G. Chételat,et al.  Region-Specific Hierarchy between Atrophy, Hypometabolism, and β-Amyloid (Aβ) Load in Alzheimer's Disease Dementia , 2012, The Journal of Neuroscience.

[25]  R. Tanzi.  The genetics of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[26]  Paul Edison,et al.  A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[28]  A. Wall,et al.  Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers , 2012, Neurology.

[29]  V. Marchesi.  Alzheimer's disease 2012: the great amyloid gamble. , 2012, The American journal of pathology.

[30]  S. Robinson,et al.  Reactive astrocytes give neurons less support: implications for Alzheimer's disease , 2012, Neurobiology of Aging.

[31]  Ove Almkvist,et al.  Evidence for Astrocytosis in Prodromal Alzheimer Disease Provided by 11C-Deuterium-L-Deprenyl: A Multitracer PET Paradigm Combining 11C-Pittsburgh Compound B and 18F-FDG , 2012, The Journal of Nuclear Medicine.

[32]  A. Nordberg.  Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development , 2011, Alzheimer's Research & Therapy.

[33]  Roger N Gunn,et al.  An 18-kDa Translocator Protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28 , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[34]  Eric Westman,et al.  Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation , 2011, Neurobiology of Aging.

[35]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[36]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[37]  C. Lyketsos.  Commentary on “Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.” New criteria for a new era , 2011, Alzheimer's & Dementia.

[38]  Chengjie Xiong,et al.  Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease , 2011, Alzheimer's Research & Therapy.

[39]  A. Nordberg,et al.  Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer’s disease , 2010, Brain : a journal of neurology.

[40]  S. Faraone,et al.  Review Article: Genetics of Alzheimer Disease , 2010, Journal of geriatric psychiatry and neurology.

[41]  Chengjie Xiong,et al.  YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease , 2010, Biological Psychiatry.

[42]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[43]  A. Verkhratsky,et al.  Astrocytes in Alzheimer’s disease , 2010, Neurotherapeutics.

[44]  R. Veerhuis,et al.  Neuroinflammation – An Early Event in Both the History and Pathogenesis of Alzheimer’s Disease , 2010, Neurodegenerative Diseases.

[45]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[46]  H. Engler,et al.  PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.

[47]  A. Korczyn.  The amyloid cascade hypothesis , 2008, Alzheimer's & Dementia.

[48]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[49]  H. Engler,et al.  Evidence for astrocytosis in ALS demonstrated by [11C](l)-deprenyl-D2 PET , 2007, Journal of the Neurological Sciences.

[50]  O. Almkvist,et al.  The importance of impaired physical health and age in normal cognitive aging. , 2007, Scandinavian journal of psychology.

[51]  A. Iafrate,et al.  Expression of Oligodendroglial and Astrocytic Lineage Markers in Diffuse Gliomas: Use of YKL-40, ApoE, ASCL1, and NKX2-2 , 2006, Journal of neuropathology and experimental neurology.

[52]  N. Volkow,et al.  Translational Neuroimaging: Positron Emission Tomography Studies of Monoamine Oxidase , 2005, Molecular Imaging and Biology.

[53]  Karl J. Friston,et al.  Unified segmentation , 2005, NeuroImage.

[54]  H. Arias,et al.  The role of inflammation in Alzheimer's disease. , 2005, The international journal of biochemistry & cell biology.

[55]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[56]  Alexander Hammers,et al.  Three‐dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe , 2003, Human brain mapping.

[57]  N. Volkow,et al.  Age-Related Increases in Brain Monoamine Oxidase B in Living Healthy Human Subjects , 1997, Neurobiology of Aging.

[58]  P. Mcgeer,et al.  The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases , 1995, Brain Research Reviews.

[59]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[60]  C. Halldin,et al.  Quantitative localization of human brain monoamine oxidase B by large section autoradiography using l-[3H]deprenyl , 1991, Brain Research.

[61]  A. Rossi,et al.  Cortical projection of putative group Ib afferent fibres from the human forearm , 1991, Brain Research.

[62]  Karl Pearson F.R.S..  LIII. On lines and planes of closest fit to systems of points in space , 1901 .

[63]  D. Balota,et al.  Clinical and psychological characteristics of the initial cohort of the Dominantly Inherited Alzheimer Network (DIAN). , 2014, Neuropsychology.

[64]  J. Molinuevo,et al.  Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.

[65]  P. Mcgeer,et al.  Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. , 2010, Journal of Alzheimer's disease : JAD.

[66]  L. Eriksson.  Multi- and megavariate data analysis , 2006 .

[67]  Pavan Reddy,et al.  Recent Advances and Future Directions , 2004 .

[68]  M. Rossor,et al.  Familial and sporadic Alzheimer's disease , 2001 .

[69]  L. Zhou,et al.  Amyloid-beta 25-35 peptide induces expression of monoamine oxidase B in cultured rat astrocytes. , 2000, Acta pharmacologica Sinica.